PubMed · 17098957
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Eddie Vos. 2006-11-07. Multitherapy for diabetes.. https://doi.org/10.1503/cmaj.1060019
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
We have prospectively evaluated the risk of incident coronary events in association with serum total homocysteine in patients with preexisting chronic coronary heart disease. A nested case-control design was used. Total homocysteine concentration was measured in baseline fasting serum samples from patients with chronic coronary heart disease enrolled in the Bezafibrate Infarction Prevention Study (n = 3,090) who developed coronary events during 6.2 years of follow-up (n = 69). They were matched for age and gender with controls without subsequent cardiovascular events. Elevated homocysteine levels were associated with 2.5 times higher risk of subsequent coronary events and each 5 mumol/l increment was associated with a 25% higher risk.
Six antihyperlipidemic agents-bezafibrate, ciprofibrate, clofibrate, clofibric acid, fenofibrate and gemfibrozil were separated by means of capillary electrophoresis, using unmodified fused silica tubing of 75 microm internal diameter and 87 cm length (65 cm to the UV detector at 227 nm). Migration time and selectivity were examined in differing pH of separation buffer, varying separation voltage and differing temperature. Optimal separation was achieved using 1/15 M phosphate buffer pH 10, 240 V/cm at 25 degrees C. The optimal separation conditions were then used to elaborate the method of quantitation of bezafibrate, ciprofibrate and gemfibrozil in Bezamidin, Lipanor and Gemfibral pharmaceuticals. The clofibric acid was used as internal standard. The calibration curve was constructed from 0.2 to 0.8 mg/ml of each compound and 0.5 mg/ml of internal standard. The calibration data were proved to be linear by Mandel and Lack-of-fit tests. Statistical evaluation of results proved proper recovery of elaborated method (102.42, 97.32 and 101.51%, respectively) and good repeatability (9.51, 5.52 and 11.15%, respectively). The linearity of recovery was also tested by analyzing increasing amount of the samples. Three fortified samples of each drug were also analyzed to perform additional accuracy validation.
BACKGROUND: The use of steatotic livers is associated with increased primary nonfunction in liver transplantation. To reduce the risk of liver injury, we applied a short-term combination therapy of diet, exercise and drugs for 11 living-donor liver transplantation (LDLT) candidates with steatosis. METHODS: Subjects were treated with a protein-rich (1000 kcal/day) diet, exercise (600 kcal/day), and bezafibrate (400 mg/day) for 2-8 weeks. RESULTS: The treatment significantly improved macrovesicular steatosis (30+/-4% vs. 12+/-2% [mean+/-SEM], P=0.0028). Body weight and BMI were significantly reduced (73.7+/-3.2 kg vs. 66.9+/-2.9 kg, P=0.0033, 26.4+/-0.7 kg/m(2) vs. 24.1+/-0.8 kg/m(2), P=0.0033). The treatment completely normalized liver function tests and lipid metabolism. Seven treated liver grafts (left lobe) were transplanted to the recipients. We compared transplanted graft function and resected liver function of donors using parameters such as peak total bilirubin, prothrombin time at postoperative day 3, and peak alanine aminotransferase between treated liver (n=7) and donor liver without hepatic steatosis (n=37). The transplanted grafts showed good liver functions, and there was no difference between them with respect to functional parameters. The treated donors also showed good liver functions, and no significant differences in functional parameters. CONCLUSIONS: The results of this study indicate that our short-term treatment effectively reduced steatosis and contributed to safer LDLT. Our findings also suggest that even severely steatotic livers can be used for LDLT grafting subsequent to our short-term treatment regimen.